Results 21 to 30 of about 2,108 (191)
Real-world outcomes of faricimab in treating diabetic macular edema up to two years [PDF]
Indian Journal of OphthalmologyPurpose: To evaluate real-world outcomes of faricimab in treating diabetic macular edema (DMO) in treatment-naive and treatment-switch patients. Design: Retrospective audit.
Tanvi Khetan +4 more
doaj +2 more sources
Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration. [PDF]
, 2023 Nowadays; intravitreal anti-vascular endothelial growth factor (VEGF) drugs are considered the first-line therapeutic strategy for treating macular exudative diseases; including wet age-related macular degeneration (w-AMD) and diabetic macular edema (DME)
Ferro Desideri, Lorenzo +3 more
core +1 more source
Case Reports in Ophthalmology, 2023 This case report describes a 78-year-old patient who developed a tear of the retinal pigment epithelium (RPE) during faricimab (Vabysmo®) therapy. After three consecutive intravitreal aflibercept (Eylea®) injections with persistent disease activity ...
Christoph R Clemens +3 more
doaj +1 more source
Current and Emerging Pharmacologic Therapies for Diabetic Retinopathy. [PDF]
PharmacotherapyABSTRACT Diabetic retinopathy, a prevalent microvascular complication of diabetes mellitus, is a leading cause of blindness among adults in developed countries. Risk factors include prolonged duration of diabetes, elevated glycosylated hemoglobin levels, hypertension, and dyslipidemia, with rapid glucose reduction also increasing risk for developing ...
Clements JN, Mesawich J, Twisdale C.
europepmc +2 more sources
International Journal of Retina and Vitreous, 2023 Background Intravitreal injection (IVI) of antibody biologics is a key treatment approach in ophthalmology. Pharmaceutical compounding and storage of prefilled syringes for IVI must take place without impairing the structure and function of the biologics.
Øystein Kalsnes Jørstad +9 more
doaj +1 more source
Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration
Scientific Reports, 2023 Though vascular endothelial growth factors (VEGF) and other proangiogenic factors, such as angiopoietins (Ang), may be involved in the development of neovascular age-related macular degeneration (nvAMD), only drugs that inhibit the VEGF family are ...
Ryosuke Tamiya +12 more
doaj +1 more source
A post hoc Evaluation of Data from the HAWK and HARRIER Trials [PDF]
, 2022 Funding Information: Development of this publication was funded by Novartis Pharma AG including medical writing and editorial assistance. The sponsor participated in data analysis, interpretation of the data, and review of the manuscript.
B, Guruprasad B. +10 more
core +1 more source
Clinical Ophthalmology, 2023 Ella H Leung, Daniel J Oh, Shannon E Alderson, Joshlynn Bracy, Mia McLeod, Litzi I Perez, Alexander Bottini, David Chin Yee, Krishna Mukkamala Georgia Retina, Atlanta, GA, USACorrespondence: Ella H Leung, 833 Campbell Hill St NW, Suite 300, Marietta, GA,
Leung EH +8 more
doaj
The role of inflammation and neurodegeneration in diabetic macular edema [PDF]
, 2021 The pathogenesis of diabetic macular edema (DME) is complex. Persistently high blood glucose activates multiple cellular pathways and induces inflammation, oxidation stress, and vascular dysfunction.
Amato A. +8 more
core +1 more source
Pharmacological ResearchBackground: Faricimab stands as the inaugural and sole bispecific antibody approved by the US Food and Drug Administration (FDA) for intravitreal injection. Nonetheless, the efficacy and safety of intravitreal faricimab remained uncertain.
Guanran Zhang +5 more
doaj +1 more source